about
Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasisThe EMBARC European Bronchiectasis Registry: protocol for an international observational studyRisk factors of A/H1N1 etiology in pneumonia and its impact on mortality.Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia.Thrombocytosis is a marker of poor outcome in community-acquired pneumonia.Predicting treatment failure in patients with community acquired pneumonia: a case-control study.Inflammatory response in mixed viral-bacterial community-acquired pneumoniaCompliance with guidelines-recommended processes in pneumonia: impact of health status and initial signs.Biomarkers and community-acquired pneumonia: tailoring management with biological data.Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis.Lung inflammatory pattern and antibiotic treatment in pneumoniaRisk factors of treatment failure in community acquired pneumonia: implications for disease outcome.Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in patients with acute respiratory distress syndrome and abdominal diseases: a preliminary observational studyPredictors of Severe Sepsis among Patients Hospitalized for Community-Acquired PneumoniaAetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study.Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations.Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of conceptFrom starting mechanical ventilation to ventilator-associated pneumonia, choosing the right moment to start antibiotic treatment.Effects of two inhaled corticosteroid/long-acting beta-agonist combinations on small-airway dysfunction in mild asthmatics measured by impulse oscillometryPulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis.Impact of guidelines on outcome: the evidence.Importance of Aspergillus spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study.Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia.The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia.Guidelines for the management of community-acquired pneumonia in the elderly patient.Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality: A Validation and Clinical Decision-making Study.Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia.Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia.Predicting In-Hospital Treatment Failure (≤ 7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids.Community-acquired pneumonia in the elderly: Spanish multicentre study.Pneumonia presenting with organ dysfunctions: Causative microorganisms, host factors and outcome.Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration.Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia.Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients.Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis.Severity and outcomes of community acquired pneumonia in asthmatic patients.
P50
Q26739006-0FBE74E6-769A-457C-8E45-5BF2F4511418Q28596688-BFAEB390-F063-4CD5-9156-30A42F8802BBQ30402543-8F9D4CA8-A190-4D19-B809-5B651BD56B4DQ30416138-B370325A-C4CF-45FE-908B-A7C247E3A37EQ33404581-0083C3F8-CBAC-4F2A-8469-C78BB9E0E19BQ33906338-D611F1FF-4B87-44E6-BA9A-D5B3B589F62AQ33987876-B21111AD-6699-427A-B4E3-19D1B6650A05Q34281998-5EBAD9A7-811F-4155-9C8E-BF3268E4CFDEQ34311257-A45E7F75-DF07-4BEE-9C1D-849C2B88C11CQ34419766-536D2FA3-293E-44F9-A89D-EB12FA10C286Q35083508-8BD06C0D-0BB7-486E-AA29-89D3D1BACACAQ35536279-70C21FA0-974F-4DCC-8FC1-5C0CC0BBB16AQ35566965-01C2DBDE-DFA4-4E0C-AA83-EE1D8C272034Q35883963-89081587-8F14-4A5E-AB47-D23B56B915ECQ36246945-9BFD7442-36AB-4E4A-8590-14D4CB8854A2Q36338492-84F72289-13B8-4577-B120-EB648C8FD62FQ36406243-3A0B498B-1AFE-4750-94BD-4D97BA2853B0Q36446832-A48E162C-2F12-4B9A-9145-78AEFC61B120Q36633627-150FCB3A-9F47-47DA-AD39-393D9BF25284Q36965674-5FB2AAE2-E565-4FFB-BADF-48F68040ADB6Q37095507-770D630B-CBB8-43EE-9E01-2352EAEC01A7Q37143786-FF094820-4697-43AA-B297-9489FAED667AQ37417654-100B28CC-9F86-40AA-B077-E5F60E3319B9Q37717451-34B62983-3CB8-4950-9C7F-B46FEA484122Q37878319-A2305475-65DF-4384-B5F9-4BFCCB704664Q37922289-7A21E7CC-F4EC-4254-B20B-0F420A7E31D7Q38199968-3CCB8832-51ED-4F0E-BFA3-1FB83A344462Q38416149-B2239102-5515-435B-89BE-78EEC0BC0918Q38725994-F96345D5-EB3D-4AEE-A190-16C8186DC0EAQ40177316-285FBB39-8897-4FE3-A5D8-EC2F2E51BC58Q40369913-15187F6A-A067-42EC-914A-EEA99D9B555FQ40448715-53F1F1A6-056B-452F-BB23-3307BA968222Q40564577-B9D02C66-19E3-4936-B41C-21B06207E847Q40582369-A571A383-CC9B-427C-B958-421B09661E17Q40707052-EEB7A383-E1C9-4786-B7A1-0A9458E68EA1Q41044146-F6CA7A7B-A9DE-4979-87F7-8DA505F728A9Q41092303-1901190E-7FC8-40DA-9E44-0085702DD005Q41326027-BB517804-1813-4912-8989-0261D537A310Q41525939-E4938CC5-8E46-4927-B8AE-B8824780977EQ41729752-D121F397-1C5D-418D-93CD-2D262DFFF562
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Rosario Menéndez
@ast
Rosario Menéndez
@en
Rosario Menéndez
@es
Rosario Menéndez
@nl
Rosario Menéndez
@sl
type
label
Rosario Menéndez
@ast
Rosario Menéndez
@en
Rosario Menéndez
@es
Rosario Menéndez
@nl
Rosario Menéndez
@sl
prefLabel
Rosario Menéndez
@ast
Rosario Menéndez
@en
Rosario Menéndez
@es
Rosario Menéndez
@nl
Rosario Menéndez
@sl
P214
P244
P106
P21
P213
0000 0003 8495 4508
P214
P244
n2008181192
P31
P496
0000-0002-3592-3839
P734
P735
P7859
lccn-n2008181192